Amyloid transthyretin cardiac amyloidosis: diagnosis and management
- 2 September 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Cardiovascular Therapy
- Vol. 17 (9), 673-681
- https://doi.org/10.1080/14779072.2019.1662723
Abstract
Introduction: Cardiac amyloidosis is a disorder caused by the accumulation of abnormal protein products, amyloid, in the myocardium which subsequently impairs normal heart function. Heart failure with preserved ejection fraction has been increasingly attributed to amyloidosis and the resultant restrictive cardiomyopathy it creates. Areas covered: Amyloid transthyretin (ATTR) is one of several identified amyloid products that have been pathologically implicated in cardiac amyloidosis through advanced diagnostics. Improvements in nuclear imaging techniques, particularly scintigraphy, have enabled non-invasive diagnosis where previously endomyocardial biopsy was the only option. Despite being considered a rare disease, it is likely that ATTR cardiac amyloidosis is an underdiagnosed condition which has been supported by autopsy findings in heart failure populations. This article will review ATTR cardiac amyloidosis to provide physicians with the tools they need to establish a definitive diagnosis when there is a clinical suspicion of amyloidosis and provide the most appropriate care. Expert commentary: Increased awareness and improved diagnostic techniques will lead to earlier diagnosis and a greater understanding of the clinical presentation. The anticipated increases in the prevalence of this disease due to increased clinical awareness will require, and in-part, facilitate the development of new therapies to manage this patient population.Keywords
This publication has 52 references indexed in Scilit:
- 99m Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac AmyloidosesCirculation: Cardiovascular Imaging, 2013
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II studyAmyloid, 2012
- Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patientsBlood, 2012
- The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved DrugJournal of Molecular Biology, 2012
- Characterizing the admixed African ancestry of African AmericansGenome Biology, 2009
- Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosisThe Journal of Pathology, 2008
- Amyloid fibrilsPrion, 2008
- Amyloid deposits in transthyretin‐derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphologyThe Journal of Pathology, 2005
- The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosisProceedings of the National Academy of Sciences of the United States of America, 2001